| Line Item | 2025-12-31 | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $26K | -7.1% | +8.3% |
| Cost of Revenue | $0 | — | -100.0% |
| R&D Expense | $1.1M | +23.5% | -36.0% |
| SG&A Expense | $1.6M | -6.0% | -4.3% |
| Operating Income | -$2.8M | -4.4% | +20.7% |
| Income Tax | $0 | -100.0% | — |
| Net Income | -$2.7M | -5.7% | +21.9% |
| EPS (Basic) | -$1.03 | -5.1% | -442.1% |
| EPS (Diluted) | -$1.03 | -5.1% | -442.1% |
| Line Item | 2025-12-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $4.3M | -35.8% | +269.3% |
| Accounts Receivable | $33K | +3.1% | +26.9% |
| Current Assets | $6.0M | -20.4% | +187.7% |
| Total Assets | $7.0M | -28.1% | +81.1% |
| Current Liabilities | $2.5M | +1.1% | -15.7% |
| Total Liabilities | $2.5M |
| Line Item | 2025-12-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$8.6M | — | — |
| Capital Expenditures | $0 | — | — |
| Investing Cash Flow | $0 | — | — |
| Financing Cash Flow | $1.6M | — | — |
| Free Cash Flow | -$8.6M | — | — |
| -27.6% |
| Stockholders' Equity | $4.4M | -37.1% | +1120.1% |